Evaluation of corin and copeptin as novel biomarkers for polycystic ovary syndrome – diagnostic accuracy and associations with cardiometabolics
DOI:
https://doi.org/10.15584/ejcem.2025.3.27Keywords:
copeptin, corin, dyslipidemia, insulin resistanceAbstract
Introduction and aim. Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects 5–18% of women of reproductive age and is intricately linked to metabolic dysfunction and cardiovascular risks. This study aimed to evaluate the diagnostic utility of copeptin and corin as potential biomarkers in PCOS and their association with cardiometabolic risk factors.
Material and methods. This case-control study included 60 women diagnosed with PCOS (Rotterdam criteria) and 30 healthy controls. Serum levels of copeptin and corin and metabolic parameters were measured using enzyme-linked immunosorbent assay kits. Statistical analyses included receiver operating characteristic (ROC) curves, logistic regression, and correlation tests.
Results. The results revealed significantly elevated corin (1450.23±264.91 vs. 619.17±159.19 pg/mL, p<0.001) and copeptin levels (5.81±1.66 vs. 2.46±0.64 ng/mL, p<0.001) in patients with PCOS compared to controls. Both biomarkers were strongly correlated with insulin resistance (HOMA-IR: r=0.648 for corin and r=0.750 for copeptin) and dyslipidemia. ROC analysis demonstrated exceptional associative biomarker precisions for corin (AUC=1.00) and copeptin (AUC=0.89). Univariate regression identified corin (odds ratio [OR]=1.018) and copeptin (OR=1.344) as independent predictors of PCOS.
Conclusion. This study identified plasma corin and copeptin levels as potential biomarkers for PCOS diagnosis and risk stratification. Elevated corin levels predict infertility, while copeptin levels correlate with metabolic dysfunction, particularly in obese, insulin resistant phenotypes.
Downloads
References
Che Y, Yu J, Li YS, Zhu YC, Tao T. Polycystic Ovary Syndrome: Challenges and Possible Solutions. J Clin Med. 2023;12(4):1500. doi: 10.3390/jcm12041500
Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668-680.
Forslund M, Melin J, Stener‐Victorin E, et al. International evidence‐based guideline on assessment and management of PCOS-A Nordic perspective. Acta Obstet Gynecol Scand. 2024;103(1):7-12. doi: 10.1111/aogs.14725
Joham AE, Piltonen T, Lujan ME, Kiconco S, Tay CT. Challenges in diagnosis and understanding of natural history of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2022;97(2):165-173.
Chang KJ, Chen JH, Chen KH. The Pathophysiological Mechanism and Clinical Treatment of Polycystic Ovary Syndrome: A Molecular and Cellular Review of the Literature. Int J Mol Sci. 2024;25(16). doi: 10.3390/ijms25169037
Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics. 2015;70(11):765-769. doi: 10.6061/clinics/2015(11)09
González F. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300-305. doi: 10.1016/j.steroids.2011.12.003
Yang Y, Ding M, Di N, Azziz R, Yang D, Zhao X. Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements. J Clin Lab Anal. 2019;33(3):e22699. doi: 10.1002/jcla.22699
Chen W, Pang Y. Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites. 2021;11(12). doi: 10.3390/metabo11120869 Akram W, Fadhil A, Nori W. Unveiling Systemic Immune Inflammation Index Correlations in Women with Polycystic Ovary Syndrome: A Cross-sectional Study. Al-Rafidain J Med Sci. 2024;6(2):156-161.
Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020;105(8):e2695-e2709. doi: 10.1210/clinem/dgaa285
Lentscher JA, Decherney AH. Clinical presentation and diagnosis of polycystic ovarian syndrome. Clin Obstet Gynecol. 2021;64(1):3-11. doi: 10.1097/GRF.0000000000000563
Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):1-8Marchiani S, Tamburrino L, McPherson N, Baldi E. The role of obesity and metabolic syndrome in couple infertility. Front Endocrinol (Lausanne). 2021;12:784716. doi: 10.3389/fendo.2021.784716
Görkem Ü, Yıldırım E. Copeptin: A potential marker for the prediction of poor ovarian reserve in the ınfertile women. Turkish J Obstet Gynecol. 2022;19(4):281. doi: 10.4274/tjod.galenos.2022.55856
Ali AI, Hassan WNM, Alrawi S. A copeptin as a predictor marker for insulin resistance among women with polycystic ovary syndrome. Curr Womens Health Rev. 2022;18(4):67-72.
Franzén A, Pikkemaat M, Melander O, Bennet L, Enhörning S. The association of copeptin with metabolic risk markers is modified by region of origin. Sci Rep. 2023;13(1):19651. doi: 10.1038/s41598-023-46908-0
Li H, Zhang Y, Wu Q. Role of corin in the regulation of blood pressure. Curr Opin Nephrol Hypertens. 2017; 26(2):67-73.
Ibrahem MA moniem, Saber Al-Karamany A, Esawy MM, Elasy AN. Plasma Corin: A New Biochemical Marker for Polycystic Ovary Syndrome. Reprod Sci. 2024;31(8):2219- 2227. doi: 10.1007/s43032-024-01531-w
Zhang C, Chen Y, Sun S, et al. A conserved LDL-receptor motif regulates corin and CD320 membrane targeting in polarized renal epithelial cells. Elife. 2020;9:e56059. Doi: 10.7554/eLife.56059
Spinelli A, Buoncristiano M, Nardone P, et al. Thinness, overweight, and obesity in 6‐to 9‐year‐old children from 36 countries: The World Health Organization European Childhood Obesity Surveillance Initiative-COSI 2015-2017. Obes Rev. 2021;22:e13214. doi: 10.1111/obr.13214
Bakeer E, Radwan R, El Mandoury A, Abd El Rahman A, Gad M, Abd El Maksoud S. Anti-müllerian hormone as a diagnostic marker in Egyptian Infertile polycystic ovary syndrome females: correlations with vitamin D, total testosterone, dyslipidemia and anthropometric parameters. J Med Biochem. 2018;37(4):448.
Patil V, Belwalkar GJ, Nagane NS, Dhonde SP. Study of lipid profile and insulin resistance in polycystic ovarian syndrome. Int J Clin Biochem Res. 2022;9(3):272-275.
Guo F, Gong Z, Fernando T, Zhang L, Zhu X, Shi Y. The lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: a retrospective study in Chinese population. Front Endocrinol (Lausanne). 2022;13:892125. doi: 10.3389/fendo.2022.892125
Vatier C, Christin-Maitre S, Vigouroux C. Role of insulin resistance on fertility–Focus on polycystic ovary syndrome. In: Annales d’Endocrinologie. Elsevier; 2022;83:199-202.
Zhang X, Gu X, Zhang Y, Dong N, Wu Q. Corin: a key mediator in sodium homeostasis, vascular remodeling, and heart failure. Biology (Basel). 2022;11(5):717. doi: 10.3390/biology11050717
Ichiki T, Huntley BK, Heublein DM, et al. Corin is present in the normal human heart, kidney, and blood, with pro–B-type natriuretic peptide processing in the circulation. Clin Chem. 2011;57(1):40-47. doi: 10.1373/clinchem.2010.153908
Şeyhanlı Z, Demir M, Türkyılmaz FO, et al. Identification of Corin and Procalcitonin in Endometrial Flushing Fluid Between Women with Polycystic Ovary Syndrome, Endometrioma, Unexplained Subfertility, and Fertile Healthy Women. Clin Res. 2024;34(2):212-218.
Karbek B, Ozbek M, Karakose M, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome. J Ovarian Res. 2014;7:31. doi: 10.1186/1757-2215-7-31
Matta RA. Apelin-36 and Copeptin Levels in Polycystic Ovary Syndrome. J Infect Dis. 2017;3(1):3.
Coelho JM, D’CUNHA P, Shivashankara AR. Serum copeptin as a biomarker of polycystic ovarian syndrome and its correlation with metabolic syndrome components: a cross-sectional analytical study. J Clin Diagnostic Res. 2024;18(7).
Widecka J, Ozegowska K, Banaszewska B, et al. Is copeptin a new potential biomarker of insulin resistance in polycystic ovary syndrome? Ginekol Pol. 2019;90(3):115-121. doi: 10.5603/GP.2019.0021
Elboghdady AA, Abd El-Fattah AI, Mohamed ES, Saeed AM. Copeptin and Obestatin Levels in Polycystic Ovary women and their Relation to Obesity, insulin metabolism and Cardiovascular diseases. Al-Azhar Int Med J. 2020;0(0):0-0. doi: 10.21608/aimj.2020.27820.1197
Yıldırım E, Görkem Ü. Association between serum copeptin levels and non-obese normoglycemic polycystic ovary syndrome: A case control study. Turkish J Obstet Gynecol. 2024;21(4):280.
Szmygin H, Szydełko J, Matyjaszek-Matuszek B. Copeptin as a novel biomarker of cardiometabolic syndrome. Endokrynol Pol. 2021;72(5):566-571. doi: 10.5603/EP.a2021.0072
Rojas-Humpire R, Soriano-Moreno DR, Galindo-Yllu B, Zafra-Tanaka JH. Association between copeptin and metabolic syndrome: a systematic review. J Nutr Metab. 2022;2022(1):5237903. doi: 10.1155/2022/5237903
Łukaszyk E, Małyszko J. Copeptin: pathophysiology and potential clinical impact. Adv Med Sci. 2015;60(2):335-341. doi: 10.1016/j.advms.2015.07.002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
